


## Caspase-9 Inhibitor III

<b>Cat. No.:</b>	HY-136744
<b>CAS No.:</b>	403848-57-7
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>35</sub> ClN <sub>6</sub> O <sub>9</sub>
<b>Molecular Weight:</b>	587.02
<b>Target:</b>	Caspase
<b>Pathway:</b>	Apoptosis
<b>Storage:</b>	Sealed storage, away from moisture and light, under nitrogen
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 125 mg/mL (212.94 mM; Need ultrasonic)					
		Solvent Concentration	Mass			
	<b>Preparing Stock Solutions</b>			1 mg	5 mg	10 mg
		1 mM		1.7035 mL	8.5176 mL	17.0352 mL
		5 mM		0.3407 mL	1.7035 mL	3.4070 mL
10 mM			0.1704 mL	0.8518 mL	1.7035 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (3.54 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.54 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (3.54 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Caspase-9 Inhibitor III (Ac-LEHD-cmk) is a caspase-9 inhibitor. Caspase-9 Inhibitor III exhibits protective effects on ischemia-reperfusion-induced myocardial injury <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Caspase-9
<b>In Vitro</b>	Caspase-9 Inhibitor III (0.07-0.105 μM; perfused for 10 min) significantly attenuates I/R induced increase in infarct size,

---

release of lactate dehydrogenase and creatine kinase in the coronary effluent, and apoptotic index of isolated rat heart<sup>[1]</sup>. Caspase-9 Inhibitor III (30  $\mu$ M) inhibits troponin I proteolysis induced by MMP-2<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Sodhi RK, et, al. Protective effects of caspase-9 and poly(ADP-ribose) polymerase inhibitors on ischemia-reperfusion-induced myocardial injury. Arch Pharm Res. 2009 Jul;32(7):1037-43.

[2]. Castro MM, et, al. Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. Biochem Pharmacol. 2013 Aug 15;86(4):469-75.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA